Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Shoshana Keren Rosenberg"'
Autor:
Dan Levy Faber, Abed Agbarya, Ben Caspy, Moshe Lapidot, Shoshana Keren Rosenberg, Sonia Schneer, Erez Sharoni, Ronen Galili
Publikováno v:
Diseases, Vol 12, Iss 5, p 98 (2024)
Non-small cell lung cancer (NSCLC) is the most common pulmonary malignancy, frequently diagnosed at an advanced stage (III/IV). Patients in the Locally Advanced Stage Subgroup (IIIA) are relatively few, yet compose heterogenic phenotypes, posing a di
Externí odkaz:
https://doaj.org/article/07493e40f53344cc870b584c86eefc62
Autor:
Miri Cohen, Yosi Shamay, Johanna Czamanski-Cohen, Katerina Shulman, Shoshana Keren Rosenberg, Mahmoud Abu-Amna, Ilit Turgeman, Ludmila Merkin Livshits, Revital Birenboim, Monica Dines, Gil Bar-Sela
Publikováno v:
Cells, Vol 12, Iss 20, p 2471 (2023)
Substantial evidence has accumulated showing that psychological distress affects immune regulation, the response to cancer treatment, and survival. The effect of psychological parameters on the effectiveness of immune checkpoint inhibitor (ICI) treat
Externí odkaz:
https://doaj.org/article/716e0e3ef40244f088c1ade32faa8ad1
Autor:
Gad Rennert, Maya Gottfried, Hedy S Rennert, Flavio Lejbkowicz, Meira Frank, Ilana Cohen, Shiri Kelt, Abed Agbarya, Elizabeta Dudnik, Julia Dudnik, Rivka Katznelson, Moshe Mishali, Natalie Maimon Rabinovich, Hovav Nechushtan, Amir Onn, Shoshana Keren Rosenberg, Mariana Wollner, Alona Zer, Jair Bar, Naomi Gronich
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100934- (2021)
Purpose: A substantial fraction of all non-small cell lung cancers(NSCLC) carry a mutation in the EGFR gene for which an effective treatment with anti-tyrosine kinases(TKIs) is available. We studied the long term survival of these patients following
Externí odkaz:
https://doaj.org/article/26a31ca9e38842c584e0074d2e96db7d
Autor:
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Cufer, Hadas Gantz Sorotsky, Sayed M. S. Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition ( MET ) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which
Externí odkaz:
https://doaj.org/article/0bbcd42c11e74cbfb91361945db11f28
Autor:
Nir Peled, Laila C. Roisman, Esther Levison, Julia Dudnik, Elena Chernomordikov, Norman Heching, Elizabeth Dudnik, Shoshana Keren-Rosenberg, Hovav Nechushtan, Ayman Salhab, Dov Hershkovitz, Shlomo Tsuriel, Victoria Hannes, Ofer Rotem, Irina Lazarev, Rachel Lichtenberg, Inbal S. Granot, Bilal Krayim, Walid Shalata, Daniel Levin, Yanay Krutman, Aaron M. Allen, Philip Blumenfeld, Konstantin Lavrenkov, Waleed Kian
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics.
Autor:
Nir Peled, Waleed Kian, Edna Inbar, Iris M Goldstein, Melanie Zemel, Ofer Rotem, Anna B Rozenblum, Hovav Nechushtan, Elizabeth Dudnik, Daniel Levin, Alona Zer, Shoshana Keren-Rosenberg, Shlomit Yust-Katz, Vered Fuchs, Areen A Remilah, Ilan Shelef, Laila C Roisman
Publikováno v:
Neuro-oncology advances. 4(1)
Background Osimertinib is selective for both epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. While intracranial activity of osimertinib is documented in larger trials, a prospective study f
Autor:
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Cufer, Hadas Gantz Sorotsky, Sayed M. S. Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair
Publikováno v:
Therapeutic Advances in Medical Oncology, 14. SAGE Publications Inc.
Therapeutic advances in medical oncology, vol. 14, pp. 1-22, 2022.
Illini, O, Fabikan, H, Swalduz, A, Vikström, A, Krenbek, D, Schumacher, M, Dudnik, E, Studnicka, M, Öhman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program ', Therapeutic Advances in Medical Oncology, vol. 14 . https://doi.org/10.1177/17588359221103206, https://doi.org/10.1177/17588359221103206
Therapeutic advances in medical oncology, vol. 14, pp. 1-22, 2022.
Illini, O, Fabikan, H, Swalduz, A, Vikström, A, Krenbek, D, Schumacher, M, Dudnik, E, Studnicka, M, Öhman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program ', Therapeutic Advances in Medical Oncology, vol. 14 . https://doi.org/10.1177/17588359221103206, https://doi.org/10.1177/17588359221103206
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition ( MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db862aef7575b35683811d5d7626aa21
https://research.vumc.nl/en/publications/592f783c-ba18-49d9-bc6f-f98cf8baa811
https://research.vumc.nl/en/publications/592f783c-ba18-49d9-bc6f-f98cf8baa811
Autor:
Mor Moskovitz, Elizabeth Dudnik, Sivan Shamai, Yakir Rotenberg, Noa Popovich-Hadari, Mira Wollner, Alona Zer, Maya Gottfried, Moshe Mishaeli, Shoshana Keren Rosenberg, Amir Onn, Ofer Merimsky, Damien Urban, Nir Peled, Natalie Maimon, Jair Bar
Publikováno v:
The oncologist. 27(1)
Objectives ALK inhibitors (ALKi) are the standard-of-care treatment for metastatic ALK-rearranged non-small cell lung cancer (NSCLC) in the first- and second-line setting. We conducted a real-world multi-institutional analysis, aiming to compare the
Publikováno v:
Translational Lung Cancer Research. 5:443-445
Oncologists are frequently asked about herbal remedies claiming to "cure" cancer, or at least delay its progression. While complementary and integrative medicine (CIM) should be aimed primarily at improving quality-of-life (QOL) related concerns, "wo
Autor:
Rivka Katsnelson, Arnold Cyjon, Maya Gips, Ofer Merimsky, Maya Gottfried, Amir Onn, Nili Peylan-Ramu, Nir Peled, Hadas Gantz Sorotsky, Haim Biran, Shoshana Keren Rosenberg, Hovav Nechushtan, Dov Flex, Jair Bar, Julia Dudnik
Publikováno v:
Lung. 192(5)
Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medic